Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Butyrate vs Tributyrin: their evidence isn't directly comparable (one is unscored); they work on different things and are often used together, not either/or. Take the 60-second quiz for a pick tailored to your goals.
Butyrate wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Likely helps
9 of 9 studies with measurable effects showed benefit.
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (1)
Outcomes where both Butyrate and Tributyrin have evidence — compare verdict strength side-by-side.
300-600mg sodium/calcium butyrate, 2-3x daily
With meals, Spread throughout day
Enteric-coated sodium or calcium butyrate
500 mg three times daily (1.5 g/day) — the only supplement-realistic dose ever tested in humans, used in the 30-day open-label Parkinson's study. Three times daily is not optional: plasma butyrate is gone by 5 hours after a dose, which is precisely why the second Phase I study abandoned once-daily dosing
Three times daily, spread across the day, Do not consolidate into a single daily dose — plasma butyrate is gone by 5 hours
Plain oral tributyrin, dosed three times daily
Redundant rather than harmful. Critically, the clinical trial record belongs to the SALT, not the prodrug: trials of sodium butyrate in IBS and inflammatory bowel disease are evidence about sodium butyrate. Tributyrin's entire human evidence base is 50 people across three uncontrolled studies, none placebo-controlled and none meeting an efficacy endpoint.
No reason to take both. If you want the compound with human clinical trials behind it, that is sodium butyrate. Tributyrin's case rests on a distal-colonic-delivery claim the evidence does not support — it was rapidly cleaved in the stomach compartment of a validated gut model.
2-4 weeks
4-8 weeks
Within hours
n/a
n/a
n/a
Perturbations in Gut Microbiota Composition in Psychiatric Disorders: A Review and Meta-analysis
JAMA psychiatry (2021) · Meta analysis · n=1519
There was a small decrease in phylogenetic diversity (SMD = -0.24; 95% CI, -0.47 to -0.001) and no significant differences in Shannon and Simpson indices.
Dietary fiber intervention on gut microbiota composition in healthy adults: a systematic review and meta-analysis
The American journal of clinical nutrition (2018) · Meta analysis · n=2099
Dietary fiber intervention, particularly involving fructans and galacto-oligosaccharides, leads to higher fecal abundance of Bifidobacterium and Lactobacillus spp. but does not affect α-diversity.
Efficacy of a postbiotic and its components in promoting colonic transit and alleviating chronic constipation in humans and mice
Cell reports. Medicine (2025) · Rct · n=110
A randomized, double-blind, placebo-controlled crossover trial involving 110 adults with chronic constipation (Rome IV criteria) demonstrates that a 3-week Probio-Eco intervention significantly improves constipation symptoms, stool straining, and worry scores.
Dietary tributyrin supplementation in Parkinson's disease: An open-label target engagement study.
Neurotherapeutics (2026) · Open label · n=17
OPEN-LABEL with NO control group and NO blinding — the design cannot separate drug effect from expectation or natural variation
Clinical and pharmacologic study of tributyrin: an oral butyrate prodrug.
Cancer Chemother Pharmacol (2003) · Open label · n=20
20 patients with advanced solid tumours treated at 150-200 mg/kg three times daily; uncontrolled Phase I
Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors.
Clin Cancer Res (1998) · Open label · n=13
13 patients treated with escalating doses of 50 to 400 mg/kg/day, once daily for 3 weeks then a 1-week rest; uncontrolled Phase I
Based on SCFA studies showing 44% butyrate increase with Mediterranean diet intervention and gut barrier integrity improvements. Conservative estimates due to limited direct butyrate supplementation RCTs. Effectiveness varies significantly by form - tributyrin forms may show higher bioavailability.
AI-estimated from published studies. Interpret as directional guidance.
Butyrate has gradable evidence while Tributyrin has insufficient evidence to score and wins in 2 of 3 categories.
Redundant rather than harmful. Critically, the clinical trial record belongs to the SALT, not the prodrug: trials of sodium butyrate in IBS and inflammatory bowel disease are evidence about sodium butyrate. Tributyrin's entire human evidence base is 50 people across three uncontrolled studies, none placebo-controlled and none meeting an efficacy endpoint. No reason to take both. If you want the compound with human clinical trials behind it, that is sodium butyrate. Tributyrin's case rests on a distal-colonic-delivery claim the evidence does not support — it was rapidly cleaved in the stomach compartment of a validated gut model. Consult a healthcare provider for personalized advice.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.